BD&L Summit for Life Sciences

Unlock the potential of a deal through optimizing business development activities and transactional excellence

San Francisco, CA, United States

In order to effectively evaluate any new business development opportunities and ensure that the true value of a transaction has been realized, while forecasting the probability of both development and commercial success, life science companies need to ensure the right internal experts are involved in the evaluation process. This calls for the development and continuous improvement of a formal process that will allow organizations to efficiently and effectively evaluate, negotiate, manage, and close a transaction. The 2nd BD&L Summit serves as an open forum for cross-functional business development teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements and M&A deals.


  • Explore flexible partnership models spanning the breadth of drug discovery and development
  • Consider Implications of Today's Reimbursement Environment on the Deal-Making Landscape
  • Hear how to create a unique position of leverage during negotiations with multiple parties
  • Explore patent litigation issues and trends and their impact on life science BD&L
  • Identify key business goals and map out a clear strategy for potential M&As with respect to tax inversion, consolidation, divestitures, and narrowing strategic focus to maximize portfolio value


  • Neil Abdollahian, M.S., M.B.A., CIDARA THERAPEUTICS, Chief Business Officer
  • Philip Gutry, RONOS BIO, Chief Business Officer
  • Christopher Haskell, Ph.D., BAYER, Vice President, Head Open Innovation Center - North America West
  • Olga Kay, J.D., Ph.D., ROCHE MOLECULAR SOLUTIONS, Senior IP Counsel
  • Sheldon L Koenig, MBA, PORTOLA PHARMACEUTICALS, Executive Vice President and Chief Commercial Officer
  • John Krayacich, LEO PHARMA, Senior Vice President and Head, Global Business Development
  • Jennifer Leeds, Ph.D., NOVARTIS, Executive Director, BD&L
  • Linus S Lin, Ph.D., ELI LILLY, Managing Director, Chorus
  • Antoun Nabhan, J.D., PEAR THERAPEUTICS,Vice President, Corporate Development
  • Jay Parrish, VIR BIOTECHNOLOGY, Chief Business Officer
  • Karah Parschauer, ULTRAGENYX, EVP, General Counsel
  • David Slack, MBA, VIRACTA THERAPEUTICS, Chief Business Officer

The agenda is not yet available for this event.
Follow this event to receive an alert when the agenda becomes available.


Hyatt Centric Fisherman's Wharf
555 North Point Street, 94133
San Francisco, CA, USA

To make reservations guests can call 888-591-1234 and request the negotiated rate for this 2nd BD&L Summit. The group rate is available until February 18, 2020. Please book your room early, as rooms available at this rate are limited. To make reservations online click here.